Impact of coronary lesion complexity on drug-eluting stent outcomes in patients with and without diabetes mellitus: analysis from 18 pooled randomized trials

Elvin Kedhi; Philippe Généreux; Tullio Palmerini; Thomas C McAndrew; Helen Parise; Roxana Mehran; George D Dangas; Gregg W Stone

doi:10.1016/j.jacc.2014.01.064

Impact of coronary lesion complexity on drug-eluting stent outcomes in patients with and without diabetes mellitus: analysis from 18 pooled randomized trials

J Am Coll Cardiol. 2014 May 27;63(20):2111-2118. doi: 10.1016/j.jacc.2014.01.064. Epub 2014 Mar 13.

Authors

Elvin Kedhi¹, Philippe Généreux², Tullio Palmerini³, Thomas C McAndrew⁴, Helen Parise⁴, Roxana Mehran⁵, George D Dangas⁵, Gregg W Stone⁶

Affiliations

¹ Isala Klinieken, Zwolle, the Netherlands.
² New York-Presbyterian Hospital/Columbia University Medical Center, New York, New York; Cardiovascular Research Foundation, New York, New York; Hôpital du Sacré-Coeur de Montréal, Montréal, Québec, Canada.
³ Dipartimento Cardiovascolare, Policlinico Sant' Orsola, Bologna, Italy.
⁴ Cardiovascular Research Foundation, New York, New York.
⁵ Cardiovascular Research Foundation, New York, New York; Icahn School of Medicine at Mount Sinai, New York, New York.
⁶ New York-Presbyterian Hospital/Columbia University Medical Center, New York, New York; Cardiovascular Research Foundation, New York, New York. Electronic address: gs2184@columbia.edu.

PMID: 24632279
DOI: 10.1016/j.jacc.2014.01.064

Abstract

Objectives: The aim of this study was to investigate whether baseline lesion complexity affects drug-eluting stent (DES) outcomes according to diabetic status.

Background: Previous studies have reported conflicting results regarding DES safety and efficacy in patients with and without diabetes mellitus (DM).

Methods: Patient-level data from 18 prospective randomized trials were pooled. DES treatment outcomes in patients with versus without DM were analyzed in 2 propensity score-matched groups further stratified according to lesion complexity (American College of Cardiology and American Heart Association class A/B1 vs. B2/C). Remaining baseline differences were adjusted for by multivariate analysis.

Results: DM was present in 3,467 of 18,441 patients (18.8%). DM was a predictor of 1-year repeat revascularization (target lesion revascularization: hazard ratio: 1.34; 95% confidence interval: 1.05 to 1.70; target vessel revascularization: hazard ratio: 1.40; 95% confidence interval: 1.15 to 1.72) and cardiac death or myocardial infarction (hazard ratio: 1.40; 95% confidence interval: 1.09 to 1.81). Rates of target lesion and target vessel revascularization were significantly higher in patients with versus those without DM with type B2/C lesions (8.0% vs. 4.5% and 10.6% vs. 5.9%, respectively, p < 0.0001 for both), but not in patients with only type A/B1 lesions (4.6% vs. 4.8%, p = 0.87, and 7.4% vs. 6.8%, p = 0.47, respectively), with a significant interaction between DM and lesion type observed for both endpoints (p = 0.01 and p = 0.02, respectively). No interaction was observed for death or myocardial infarction (p = 0.28).

Conclusions: In the DES era, patients with DM remain at increased risk for cardiac death or myocardial infarction. However, DM is a risk factor for repeat revascularization only in those patients with complex lesions; patients with DM and noncomplex lesions have similar rates of 1-year freedom from repeat revascularization as do patients without DM.

Keywords: diabetes mellitus; drug-eluting stent(s); prognosis.

Publication types

Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Coronary Angiography
Coronary Restenosis / complications
Coronary Restenosis / diagnostic imaging
Coronary Restenosis / surgery*
Diabetes Mellitus*
Drug-Eluting Stents*
Female
Follow-Up Studies
Humans
Male
Middle Aged
Propensity Score
Prospective Studies
Prosthesis Design
Risk Factors
Treatment Outcome